Immunitas Therapeutics

The human approach to oncology

Immunitas Therapeutics, founded by Longwood Fund, employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements. Our focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and greatly accelerates the pace of our research. The Immunitas team of scientific pioneers innovates around each step of the drug development process, first identifying novel targets, then designing therapeutic strategies, and developing key biomarkers to guide the selection of patients who may benefit from our new drugs. Immunitas launched with a $39 million Series A round of financing from Longwood Fund, Leaps by Bayer, Novartis Venture Fund, Evotec, M Ventures, and Alexandria Venture Investments. www.immunitastx.com 

Werewolf Therapeutics

Developing transformative immuno-stimulatory medicines to unleash a powerful attack on cancer

Werewolf Therapeutics is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the body’s immune response to selectively target cancer. Werewolf’s proprietary PREDATOR™ protein engineering platform combines a variety of approaches to actively silence the drug while in systemic circulation, optimize its pharmacokinetic profile, and rapidly and efficiently transform into the fully active state upon reaching the tumor microenvironment for maximum therapeutic potential. Werewolf is creating a new era of tumor-selective, systemically delivered drugs with the potential to deliver more effective, less toxic treatments for people with cancer. www.werewolftx.com

Pyxis Oncology

Developing cancer immunotherapeutics based on new insights into the tumor microenvironment

Pyxis Oncology is an immuno-oncology company focused on developing novel therapies to help patients defeat difficult to treat cancers. Built on the ground-breaking research of Dr. Thomas Gajewski, Pyxis is pursuing promising novel targets derived from the latest insights into the tumor microenvironment. Pyxis has generated preclinical data on these targets and is developing a pipeline of novel antibodies with the potential to help new patient populations not currently served by today’s immunotherapies. David Steinberg served as the company’s co-founder and CEO. Pyxis closed a $22 million Series A round of financing from Longwood Fund, Leaps by Bayer, Agent Capital, and Ipsen. www.pyxisoncology.com 


Developing Small Molecules to Target ncRNA Biology

MicroRNAs (miRNAs) are short non-coding RNAs that inhibit target gene expression by suppressing messenger RNA (mRNA) translation and/or promoting mRNA decay. It is now recognized that miRNAs are directly involved in cancer initiation, progression, and metastasis. Twentyeight-Seven is developing small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs. www.twentyeight-seven.com

TScan Therapeutics

Developing novel T cell therapeutics in cancer

TScan Therapeutics was co-founded by Longwood Fund in collaboration with Lasker Award-winner Stephen Elledge of Harvard Medical School. The novel platform allows for direct therapeutic development of anti-tumor TCRs by identification of their antigens in a genome-wide high-throughput manner, expanding the promise of immuno-oncology to patients not served by current cancer treatments. Christoph Westphal was the company’s Co-Founder and startup CEO and Longwood Principal Lea Hachigian was the company’s Co-Founder and startup President. TScan has closed two rounds of financing totaling $48 million from Longwood Fund, Google Ventures, Novartis Venture Fund, Bessemer Venture Partners, 6 Dimensions, and Novartis Institutes for BioMedical Research.

Archer Diagnostics

Addressing the bottlenecks associated with using next generation sequencing in oncogenic mutation detection by offering a robust platform for targeted sequencing.

ArcherDX is a commercial stage company utilizing novel chemistry for next generation sequencing to provide research tools to leading universities and pharmaceutical companies. ArcherDX is also developing a suite of companion diagnostics based on this technology, initially targeting mutations across numerous cancer types to enable wider adoption of precision medicine. www.archerdx.com


Manipulating metabolism to develop disease modifying therapeutics for immuno-oncology and immuno-inflammation

Sitryx Therapeutics Limited is leveraging metabolic insights into the fumarate/fumarate hydratase drug target/pathway to develop a pipeline of first-in-class small molecule drugs to treat a broad range of orphan and blockbuster indications, starting with cancer. The Company has a pipeline of projects at multiple stages of drug discovery.  

Bicycle Therapeutics

Developing a new class of medicines to treat cancer & other debilitating diseases

Bicycle Therapeutics (“Bicycle”) is pioneering a unique class of chemically synthesized medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities. Bicycles’ small size and exquisite targeting delivers rapid tumor penetration and retention while clearance rates and routes can be tuned to minimize exposure of healthy tissue and bystander toxicities. The company has entered into strategic partnerships with Biogen-spinout Bioverativ, AstraZeneca, and ThromboGenics. www.bicycletherapeutics.com


Seeks to detect cancer early, when it can be cured

GRAIL is a life sciences company whose mission is to detect cancer early when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art computer science and data science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company's investors include Amazon, Bezos Expeditions, Bill Gates Foundation, alongside strategic investors including Bristol-Myers Squibb, Arch Venture Partners, Celgene, Illumina, Johnson & Johnson Innovation, and Merck. www.grail.com


Developing the leading range of first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections

Pulmocide is developing novel small molecule inhaled medicines for the treatment of life threatening respiratory infections caused by Respiratory Syncytial Virus (RSV) and pulmonary aspergillus. The Pulmocide team has an extensive track record in the discovery and development of novel inhaled medicines for respiratory indications. Garth Rapeport M.D., Pulmocide’s CEO, was formerly the head of GlaxoSmithKline’s Respiratory Centre of Excellence for Drug Discovery, which led to the development of new long acting inhaled therapies for COPD and asthma. www.pulmocide.com

Renovia, Inc.

Innovative solutions for pelvic floor health

Renovia Inc. was formed to better diagnose, treat, and improve women's health through innovative sensor technology integrated with digital health. Its first commercial product allows precise, cost-effective visualization, and treatment of weakened pelvic floor muscles in real time, providing actionable compliance and data on women’s pelvic health. www.renoviainc.com

Axial Biotherapeutics

harnessing the link between the human gut microbiome and
the central nervous system

Dr. Westphal, Dr. Donabedian, and Mr. Aldrich founded Axial Biotherapeutics (“Axial”) in 2015 with Sarkis Mazmanian, Ph.D., of California Institute of Technology (CalTech), a recipient of the MacArthur Foundation “Genius” award. Dr. Donabedian currently serves as CEO and Mr. Aldrich serves as a director. Axial harnesses the link between the human gut microbiome and the Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders such as Autism Spectrum Disorder and Parkinson’s Disease. www.axialbiotherapeutics.com

Millendo Therapeutics

Leveraging novel biological insights to advance a portfolio of endocrine therapeutics

Millendo Therapeutics (“Millendo”) is leveraging novel biology to create transformative therapeutics for patients suffering from endocrine disorders of significant unmet need, including Prader-Willi Syndrome, Congenital Adrenal Hyperplasia, and Cushing’s Syndrome. www.millendo.com

Channel Medsystems

Developing treatments to meet the unique needs of female patients and the high standards of their healthcare providers

Channel Medsystems (“ChannelMed”) is developing treatments to meet the unique needs of female patients. The first application of ChannelMed’s novel cryothermic technology focuses on global endometrial ablation for women with heavy menstrual bleeding. The cryothermic platform at the core of this technology has the potential for multiple future applications. www.channelmedsystems.com

KalVista Pharmaceuticals

Creating a new generation of small molecule protease inhibitors

KalVista Pharmaceuticals (NASDAQ: KALV) (“KalVista”) is focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista has created a structurally diverse portfolio of oral plasma kallikrein inhibitors from which it plans to select multiple drug candidates to advance into clinical trials for HAE. In October 2017, KalVista announced a deal with Merck for $37 million upfront and milestone spayments of up to $715 million, in addition to acquiring a 9.9% ownership stake. www.kalvista.com

Recros Medica

Rotational fractional resection: A novel innovation for
Aesthetic Medicine

Recros Medica, Inc. (“Recros Medica”) is developing a new medical aesthetic technology platform (Rotational Fractional Resection) with multiple clinical applications for the treatment of skin laxity and focal aesthetic contour deformities in the submentum (under the chin), upper arms, knees, and other areas where visible scarring limits the use of traditional plastic surgery. Edward Knowlton, M.D., the founder of Recros Medica, was the inventor of Thermage and led the commercial development of Latisse. www.recrosmedica.com


the leading dermatologist-recommended skin health cosmetics company

Colorescience is a leading dermatologist-recommended skin health cosmetics company and is dedicated to repairing and protecting the skin from the damaging effects of the sun and environment. The company’s products generate significant revenue and include award-winning, high-quality, dermatologist-recommended formulations with high SPF. The Colorescience team is led by Mary Fisher who brings more than 25 years of experience in the pharmaceutical and biotechnology industries, including leading the successful sale of SkinMedica Inc. to Allergan, Inc. for $350 million. www.colorescience.com

Calithera Biosciences, Inc.

Developing oncology therapeutics that inhibit pathways critical to tumor growth and survival

Calithera Biosciences (NASDAQ: CALA) (“Calithera”) is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. www.calithera.com

Mitobridge, Inc.

developing drugs that can treat a wide range of serious diseases by modulating mitochondrial function

Mitobridge, Inc. (Mitobridge), is a leader in the emerging field of mitochondria-related drug discovery and development. The company is utilizing its innovative screening platform to identify and develop novel therapeutics that improve mitochondria function and provide treatments for mitochondrial genetic diseases, musculoskeletal and neurodegenerative disorders, as well as diseases and conditions of aging. Mitobridge’s scientific founders and advisors include world-renowned leaders in biology and mitochondrial function. In January 2018, Mitobridge was acquired by Astellas Pharmaceuticals Inc. for $225 million plus future contingent payments of up to $225 million based on the advances in clinical programs. www.mitobridge.com

PTC Therapeutics

Focused on the discovery, development and commercialization of proprietary small-molecule drugs

PTC Therapeutics (NASDAQ: PTCT) (“PTC”) is a global biopharmaceutical company focused on the discovery, development and commercialization of novel medicines using expertise in RNA biology. PTC’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC’s mission is focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. PTC’s Translarna product has been approved in Europe for the treatment of nonsense mutation Duchenne muscular dystrophy and its EMFLAZA product is approved in the United States for the treatment of Duchenne muscular dystrophy. www.ptcbio.com

Illuminoss Medical

minimally invasive solutions for the treatment of bone fractures

IlluminOss Medical (IlluminOss) has developed a platform, disruptive technology for the orthopedic trauma market. It has achieved CE Mark approval in Europe, and has filed for expanded indications. IlluminOss has received FDA approval of its treatment for impending and actual pathological fractures of the humerus, radius, and ulna from metastatic bone disease. The technology centers around image guided, minimally invasive conforming orthopedic implants that leverage its proprietary bone stabilization technology, the IlluminOss System. The IlluminOss System has been safely and effectively used internationally since 2010 for a wide variety of clinical indications. www.illuminoss.com


Novel drugs targeting the tumor microenvironment

Dr. Westphal and Mr. Aldrich founded Verastem, Inc. (NASDAQ: VSTM) (“Verastem”) in 2010 with Professors Eric Lander, Ph.D. (Broad Institute/MIT/Harvard Medical School), and Robert Weinberg, Ph.D. (Whitehead Institute/MIT), with Dr. Westphal serving as CEO and on the board of directors for several years. Verastem focuses on discovering and developing drugs to improve the survival and quality of life of cancer patients. In 2018, Verastem received approval for its lead product COPIKTRA™ (duvelisib) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies. COPIKTRA also received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. www.verastem.com

ALNARA Pharmaceuticals

Improving nutritional status and pill burden in patients with pancreatic diseases

Dr. Westphal and Mr. Aldrich founded Alnara Pharmaceuticals, Inc. (“Alnara”) in 2008 with Alexey Margolin to develop non-systemic protein therapeutics. Shortly thereafter, Alnara obtained exclusive worldwide rights to develop, manufacture and market liprotamase, a unique pancreatic enzyme replacement therapy to treat patients with cystic fibrosis. Alnara was developing the drug in conjunction with the Cystic Fibrosis Foundation. Mr. Aldrich served as chair of the board and Dr. Westphal served on the board. Alnara was sold to Eli Lilly in July of 2010, approximately six months after Longwood I invested.